Abbott LaboratoriesABT -0.04%80 Days Payable is 83.22 as of Mar. 2026, which is 1% above its 10-year median of 82.54. GuruFocus rates ABT with a GF Score™ of 80/100 and a GF Value™ of $129.49 (Significantly Undervalued). Among 795 Medical Devices & Instruments companies, Abbott Laboratories ranks better than 56.98% on this metric.
The historical rank and industry rank for Abbott Laboratories's Days Payable or its related term are showing as below:
ABT'
s Days Payable Range Over the Past 10 Years
Min: 45.33 Med: 82.54 Max: 90.38
Current: 79.73
During the past 13 years, Abbott Laboratories's highest Days Payable was 90.38. The lowest was 45.33. And the median was 82.54.
ABT's Days Payable is ranked better than 56.98% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 67.87
vs ABT: 79.73
Abbott Laboratories's Days Payable
declined
from Mar. 2025 (85.87) to Mar. 2026 (83.22).
It may suggest that Abbott Laboratoriesaccelerated paying its suppliers.
Abbott Laboratories Days Payable Related Terms
Abbott Laboratories Days Payable Historical Data
* Premium members only.
The historical data trend for Abbott Laboratories's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Abbott Laboratories's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abbott Laboratories Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Abbott Laboratories's Days Payable distribution charts can be found below:
* The bar in red indicates where Abbott Laboratories's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Abbott Laboratories's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abbott Laboratories (ABT) has a Days Payable of 83.22 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Abbott Laboratories and its competitors. This is near median its historical median of 82.54. Over the past decade, Abbott Laboratories' Days Payable has ranged from 45.33 to 90.38. According to the industry distribution chart, Abbott Laboratories ranks #342 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 43%.
Is Abbott Laboratories' Days Payable too high?
Abbott Laboratories' current Days Payable of 83.22 is near median its 10-year median of 82.54. Over the past 10 years, this metric has ranged from a low of 45.33 to a high of 90.38. The Medical Devices & Instruments industry median Days Payable is 67.87. Abbott Laboratories' value of 83.22 is 22.6% above this industry median. Based on the distribution chart, Abbott Laboratories ranks #342 out of 795 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Abbott Laboratories has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Abbott Laboratories' Days Payable compare to SYK and MDT?
According to the Medical Devices & Instruments industry distribution chart, Abbott Laboratories ranks #342 out of 795 companies for Days Payable. This puts Abbott Laboratories in the upper half of its industry. The industry median Days Payable is 67.87. Abbott Laboratories' value of 83.22 is 22.6% above this benchmark. Historically, Abbott Laboratories' own Days Payable has ranged from 45.33 to 90.38 over the past decade. While the company's 10-year median is 82.54 vs. the industry median of 67.87, Abbott Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.87, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abbott Laboratories's current Days Payable of 83.22 is 22.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Abbott Laboratories and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abbott Laboratories's current Days Payable is 83.22, which is near median its own 10-year median of 82.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbott Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Abbott Laboratories (ABT) is currently considered Significantly Undervalued. The stock's GF Value™ is $129.49, compared to a current price of $90.49 — trading 30.1% below its estimated fair value. The current Days Payable is 83.22, which is near median its 10-year median of 82.54 and 22.6% above the Medical Devices & Instruments industry median of 67.87. Abbott Laboratories' overall GF Score™ is 80/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Abbott Laboratories (ABT), the current Days Payable is 83.22 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abbott Laboratories (ABT) Overvalued in 2026?
Based on GuruFocus' analysis, Abbott Laboratories stock appears to be undervalued.
The current stock price of $90.49 is trading 30.1% below its estimated GF Value™ of $129.49.
GuruFocus considers Abbott Laboratories to be Significantly Undervalued.
Key valuation signals for ABT:
Days Payable: 83.22 (near median its 10-year median of 82.54)
GF Value™: $129.49 vs. price of $90.49 (30.1% below fair value)
Industry Position: 22.6% above the Medical Devices & Instruments median (#342 of 795)
No single metric tells the full story. See the ABT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
80GF Score
Get the complete analysis for ABT
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABT has been successfully added to your 
